This builds upon a prior report by Ge at al. (56) evaluating a preclinical selective JAK1 inhibitor for ICI-T1DM in mice and the recent successful phase 2 trial of JAKi baricitinib in spontaneous T1DM (16). Here, JAK1 is linked to type 1 diabetes mellitus.